Edgewise Therapeutics, Inc. (EWTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Edgewise Therapeutics reported revenue of $0. Net income was -$167.8M, or -$1.63 per diluted share. Operating activities generated -$143.8M of cash, leaving -$144.1M of free cash flow. At fiscal year end, Edgewise Therapeutics held $552.6M in total assets against $30.3M in total liabilities, including $61.1M of cash and equivalents.
Open the full interactive Edgewise Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Edgewise Therapeutics Key Stats
| Share Price | $36.28 |
|---|---|
| Market Cap | $3.91B |
| 52-Week Range | $14.70 – $48.35 |
| Shares Outstanding | 107.7 million (basic, 2026 Q2) |
Edgewise Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$43.2M | -$71.7M | -$114.4M | -$158.8M | -$191.4M |
| Pre-Tax Income | -$42.8M | -$67.6M | -$100.2M | -$133.8M | -$167.8M |
| Income Tax | $0 | $0 | $0 | $0 | $4,000 |
| Net Income | -$42.8M | -$67.6M | -$100.2M | -$133.8M | -$167.8M |
| Diluted EPS | -$1.14 | -$1.26 | -$1.57 | -$1.45 | -$1.63 |
Edgewise Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$40.7M | -$50.2M | -$49.0M | -$57.3M |
| Diluted EPS | -$0.39 | -$0.49 | -$0.46 | -$0.53 |
Edgewise Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $15.6M | $22.0M | $86.1M | $41.7M | $61.1M |
| Current Assets | $283.8M | $357.0M | $327.0M | $475.5M | $543.4M |
| Total Assets | $285.2M | $367.1M | $340.0M | $486.8M | $552.6M |
| Current Liabilities | $10.5M | $16.6M | $16.8M | $23.9M | $27.4M |
| Total Liabilities | $10.8M | $20.4M | $21.2M | $27.6M | $30.3M |
| Shareholders' Equity | $274.4M | $346.7M | $318.8M | $459.2M | $522.3M |
Edgewise Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$33.5M | -$52.6M | -$91.9M | -$109.0M | -$143.8M |
| Cash From Investing | -$242.2M | -$70.6M | $102.9M | -$184.7M | -$32.8M |
| Cash From Financing | $186.4M | $129.6M | $53.2M | $249.3M | $196.1M |
| Free Cash Flow | -$34.2M | -$58.2M | -$97.7M | -$110.3M | -$144.1M |
Figures from Edgewise Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Edgewise Therapeutics financials page for every line item.
Edgewise Therapeutics Company Profile
| Ticker | EWTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boulder, Colorado |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001710072 |
Frequently Asked Questions
What was Edgewise Therapeutics' revenue in fiscal 2025?
Edgewise Therapeutics (EWTX) reported revenue of $0 for fiscal 2025.
What is Edgewise Therapeutics' annual revenue history?
Edgewise Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Edgewise Therapeutics' net income in fiscal 2025?
Edgewise Therapeutics reported net income of -$167.8M for fiscal 2025.
What was Edgewise Therapeutics' earnings per share (EPS) in fiscal 2025?
Edgewise Therapeutics' diluted EPS was -$1.63 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Edgewise Therapeutics generate in fiscal 2025?
Edgewise Therapeutics generated -$144.1M of free cash flow in fiscal 2025.
What was Edgewise Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Edgewise Therapeutics reported revenue of $0.
How many shares of Edgewise Therapeutics are outstanding?
Edgewise Therapeutics reported a weighted average of 107.7 million basic shares outstanding in 2026 Q2.
What is Edgewise Therapeutics' market cap?
Based on its latest closing price, Edgewise Therapeutics (EWTX) has a market capitalization of about $3.91B.
When does Edgewise Therapeutics' fiscal year end?
Edgewise Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Edgewise Therapeutics headquartered?
Edgewise Therapeutics lists its business address in Boulder, Colorado in its SEC filings.